What Is a Stem Cell Line, and How Are They Used in Research?

When you read about a scientific finding involving stem cells, researchers almost never started from scratch. Usually, they pulled a vial from a freezer containing a "stem cell line" — a population of cells, descended from an original source, that labs worldwide can grow, share, and study using the same starting material. Understanding what a stem cell line is, and why the field leans on a relatively small number of well-documented ones, is useful before evaluating any stem cell headline. This piece covers the basic definition, how lines are established and quality-checked, why researchers prefer registered lines over deriving new ones each time, and the real limitations — genetic drift, contamination, and line-to-line variability — that even the best-characterized lines can't fully escape.

What Makes a Population of Cells a "Line"?

A stem cell line is a population of stem cells that can be grown and expanded in a lab dish — a process called cell culture — for an extended period, or in some cases indefinitely, while retaining the properties that make them useful: self-renewal (dividing without maturing into a specialized cell type) and, depending on the cell type, the potential to differentiate into one or more kinds of mature cells. NIH's Stem Cell Basics primer describes how, starting from a small original batch, scientists periodically "subculture" the growing population into new dishes, with each round called a "passage." Over successive passages, an original sample can, in principle, yield millions of genetically related descendants. Batches can also be frozen and shipped to other labs — a large part of what makes a "line," as opposed to a one-off dish of cells, useful to science at large.

How Stem Cell Lines Are Established

Lines are established from a few different starting points, and the source shapes what the line can do. Human embryonic stem cell (hESC) lines are derived from the inner cell mass of a blastocyst — an early-stage embryo, typically donated from IVF procedures that would otherwise go unused — a process that destroys the embryo and has made hESC research ethically and politically contentious since the field began. The first human embryonic stem cell lines were derived in 1998 by a team led by James Thomson at the University of Wisconsin–Madison, published in Science; that paper described five lines (H1, H7, H9, H13, H14), including one still widely used today, H9. Induced pluripotent stem cell (iPSC) lines, developed starting in 2006 by Shinya Yamanaka's lab, take a different route: ordinary adult cells, such as skin or blood cells, are reprogrammed by introducing a small set of genes that reset them to an embryonic-like state — no embryo required. Adult (somatic) stem cell lines come from tissues such as bone marrow or umbilical cord blood; some types, notably mesenchymal stem cells, expand well in culture, while others, like hematopoietic (blood-forming) stem cells, are notoriously hard to maintain long-term outside the body. Whatever the source, a newly derived line isn't ready for general use until it's characterized — tested to confirm identity, differentiation potential, and genetic normalcy.

Why Researchers Rely on Established Lines

Deriving a brand-new stem cell line for every experiment would be slow, expensive, and — for embryonic lines especially — would multiply the ethical and regulatory questions involved. Instead, the field has converged on a relatively small set of established, well-documented lines that many labs draw from in common. This matters for reproducibility: when labs on different continents both use, say, the H9 hESC line or a specific catalogued iPSC line, they're working from genetically comparable material, making it easier to compare results and build on each other's work. It also matters for oversight. In the U.S., only hESC lines meeting the NIH's ethical requirements — including documented informed consent from donors — and listed on the NIH Human Embryonic Stem Cell Registry are eligible for NIH-funded research; the registry notes known chromosomal abnormalities next to each line. Internationally, the human Pluripotent Stem Cell Registry (hPSCreg), founded under the European Commission in 2007, plays a similar role, requiring documented ethical provenance and standardized characterization data before listing a line, so researchers anywhere can find quality-assessed lines and compare data on equal footing.

What "Well-Characterized" and Registered Actually Mean

"Well-characterized" refers to a specific battery of tests, not a vague compliment. ISSCR guidelines call for labs to authenticate a line's identity (commonly via short tandem repeat, or STR, profiling — the same technique used in forensic testing), confirm it's free of mycoplasma and other microbial contamination on a regular schedule, and verify its capacity to self-renew, differentiate as expected, and maintain normal chromosomes. For iPSC lines specifically, ISSCR also calls for confirming the reprogramming genes used to create the line have been switched off, since leftover reprogramming activity can distort results. NIH registry listings similarly flag known mutations or abnormalities next to each line's entry. All of this generates a paper trail — a "Master Cell Bank" of tested, frozen stock, in ISSCR's terminology — giving other scientists real information to evaluate before building a project around a given line.

Limitations: Drift, Variability, and Contamination Risk

Even carefully characterized lines aren't static or interchangeable, and researchers who work with them are generally candid about this. One documented issue is genetic drift: as cells divide over many passages, random mutations arise, and a mutation that gives a subset of cells a growth advantage can come to dominate the population surprisingly fast — ISSCR notes this kind of takeover can happen within five to ten passages. Pluripotent lines have also been repeatedly observed to acquire recurring chromosomal changes over time, including gains affecting chromosomes 1, 12, 17, 20, and X, along with mutations in cancer-associated genes such as TP53 — changes that can alter growth rate, differentiation behavior, or tumorigenic potential, which is why ISSCR recommends periodic genetic testing and generally advises against using cells beyond roughly ten passages from a thawed stock. Contamination is a second persistent risk: cultures are vulnerable to mycoplasma and other microbial contamination, and cell biology has a long history of lines being misidentified or cross-contaminated with others — part of why authentication testing is now standard practice. Finally, lines differ from one another: studies comparing hESC lines side by side have found real differences in self-renewal and differentiation behavior, even among lines all classified as pluripotent. None of this makes stem cell lines unreliable; it means they behave like any biological reagent that changes subtly with handling, which is exactly what characterization and registry systems exist to track and disclose.

Bottom Line

A stem cell line is best understood as a shared, renewable resource: a population of cells, traced to a documented source and tested against a known standard, that different labs can grow from the same starting point instead of each working from scratch. That shared standard is what has let stem cell research become a genuinely global, cumulative enterprise — the same five human embryonic stem cell lines derived in 1998 seeded decades of subsequent work, and today's registries extend that logic to thousands of newer iPSC lines. At the same time, no line is fixed and unchanging: cells drift genetically as they divide, cultures can become contaminated, and different lines behave somewhat differently from one another. The honest picture is that stem cell lines are powerful, well-vetted tools with real, documented limitations — which is why the field has built such an elaborate infrastructure of characterization standards and public registries around them.